Alignment Healthcare (ALHC) had an impressive week, gaining over 18% to close at $6.29 per share. This strong upward movement was not limited to ALHC alone, as A.I.dvisor's analysis showed that all 16 stocks in the Managed Health Care Industry trended upwards, indicating a positive trend for the entire sector.
Looking specifically at ALHC's technical indicators, the Relative Strength Index (RSI) Oscillator is worth noting. The RSI moved out of oversold territory on April 24, which suggests a potential shift in the stock's trend from downward to upward. Traders may want to consider buying the stock or call options.
To gain a deeper understanding of the implications of this indicator, A.I.dvisor examined 15 similar instances where the RSI Oscillator left oversold territory, finding that in 12 of those cases, the stock moved higher. This gives a probability of 80% that ALHC's stock will continue to trend upward.
While technical indicators like the RSI Oscillator can provide valuable insights for traders, it's important to consider other factors as well, such as the company's financial performance. In this regard, ALHC's most recent earnings report shows promising signs.
For the fourth quarter of 2022, ALHC reported $294 million in revenue, a 34% increase from the previous year. The company's net income also saw a significant improvement, with a $9.8 million profit compared to a $15.1 million loss in the same period last year. These results suggest that the company is making positive strides towards profitability.
Furthermore, ALHC's outlook for the future is optimistic, with the company forecasting continued revenue growth in the range of 20-25% for the next fiscal year. This projection is supported by the company's recent expansion efforts, such as its acquisition of a Medicare Advantage plan in Texas.
ALHC's impressive performance this week, combined with a positive technical indicator and promising earnings report, make it an intriguing prospect for traders and investors alike. However, as with any investment, it's important to conduct thorough research and consider all relevant factors before making any decisions.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALHC advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .
ALHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on February 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALHC as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ALHC moved below its 50-day moving average on February 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALHC crossed bearishly below the 50-day moving average on February 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALHC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ALHC entered a downward trend on March 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALHC's P/B Ratio (19.493) is very high in comparison to the industry average of (3.490). ALHC has a moderately low P/E Ratio (0.000) as compared to the industry average of (21.458). ALHC's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (0.774). ALHC's Dividend Yield (0.000) is considerably lower than the industry average of (0.027). P/S Ratio (0.858) is also within normal values, averaging (0.582).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ManagedHealthCare